5-(methylthio)-α-D-ribose-1-phosphate | 68134-74-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(methylthio)-α-D-ribose-1-phosphate
• 英文别名: S-methyl-5-thio-D-ribose 1-phosphate；S-methyl-5-thio-alpha-D-ribose 1-phosphate；[(2R,3R,4S,5S)-3,4-dihydroxy-5-(methylsulfanylmethyl)oxolan-2-yl] dihydrogen phosphate
• CAS: 68134-74-7
• 化学式: C₆H₁₃O₇PS
• 分子量: 260.205
• InChiKey: JTFITTQBRJDSTL-KVTDHHQDSA-N

物化性质

• 沸点：
  546.0±60.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  142
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  甲硫腺苷 在 potassium phosphate buffer 、 rh 5'-deoxy-5'-methylthioadenosine phosphorylase 作用下， 生成 5-(methylthio)-α-D-ribose-1-phosphate 、 腺嘌呤
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates

  摘要：

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.107

文献信息

• Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US11396647B2

  公开（公告）日：2022-07-26

  Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.

  本文公开了与具有 MTA/ADO 降解酶活性的共轭多肽有关的组合物。这些共轭多肽经过设计，可在保持催化活性的同时实现最大程度的共轭。还公开了与共轭多肽相关的核酸、表达载体和宿主细胞。进一步公开的是使用包含上述内容的药物制剂治疗癌症的方法。
• Methods of treating cells containing fusion genes by genomic targeting
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US11517629B2

  公开（公告）日：2022-12-06

  The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

  本发明涉及治疗癌症或癌前病变或肿瘤患者的方法。本发明至少部分基于以下发现：特异性靶向融合基因的基因组编辑技术可诱导具有融合基因的前列腺癌细胞以外的癌细胞（如肝细胞癌细胞）中的细胞死亡。本发明提供了治疗癌症患者的方法，包括针对受试者一个或多个细胞内存在的融合基因进行基因组编辑技术，以产生抗癌效果。
• METHODS OF TREATING CELLS CONTAINING FUSION GENES BY GENOMIC TARGETING
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20190282708A1

  公开（公告）日：2019-09-19

  The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.
• METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME
  申请人：THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20200129569A1

  公开（公告）日：2020-04-30

  Provided herein are methods and compositions for the treatment of cancer by modulating the microbiome to enhance the efficacy of immune checkpoint blockade. The microbiome may be modulated by the administration of butyrate and/or butyrate-producing bacteria. Also provided herein are methods of determining a response to an immune checkpoint inhibitor by identifying if a subject has a favorable microbial profile.
• HUMAN METHYLTHIOADENOSINE/ADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER THERAPY
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20220047683A1

  公开（公告）日：2022-02-17

  Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.